Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503434 | 0.82 | MCL1 (0.68) | MCL1HPGDL3MBTL1THRBTHRA | |
| SCHEMBL10362822 | 0.78 | CYP3A4 (0.48) | MCL1CYP3A4HPGDL3MBTL1TDP1 | |
| SCHEMBL10362685 | 0.77 | CYP3A4 (0.50) | CYP3A4HPGDTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15464819 | 0.77 | MCL1 (0.70) | MCL1HPGDL3MBTL1ALDH1A1MAPT | |
| SCHEMBL10364486 | 0.77 | CYP3A4 (0.47) | CYP3A4HPGDTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10362997 | 0.76 | CYP3A4 (0.49) | CYP3A4HPGDL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL12587021 | 0.76 | CYP3A4 (0.68) | CYP3A4HPGDTDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22434873 | 0.76 | L3MBTL1 (0.59) | MCL1L3MBTL1ALDH1A1 | |
| SCHEMBL10363472 | 0.75 | CYP3A4 (0.51) | CYP3A4HPGDL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL28634310 | 0.75 | MCL1 (0.57) | MCL1L3MBTL1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034921-B2 | Chemokine receptors (CCR5); double stranded RNA; gene knockout | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | MCL1 653/4885CYP3A4 4874/4885HPGD 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.